Supernus Pharmaceuticals | SUPN - Net Income

Stock Price
49.86
Daily Change
0.10 0.20%
Monthly
1.03%
Yearly
54.60%
Q2 Forecast
48.70

Supernus Pharmaceuticals reported $-45.12M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Abbott USD 1.08B 699M Mar/2026
ANI Pharmaceuticals USD 32.35M 6.08M Dec/2025
Aurora Cannabis CAD 1.82M 53.29M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Canopy Growth CAD -62.63M 60.99M Dec/2025
Cara Therapeutics USD -5.53M 621K Sep/2025
Corcept Therapeutics USD 24.29M 4.62M Dec/2025
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Novo Nordisk DKK 26.89B 388M Dec/2025
Pacira USD 1.64M 3.8M Dec/2025
Perrigo USD -1.42B 1.43B Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Supernus Pharmaceuticals USD -45.12M 67.62M Sep/2025
United Therapeutics USD 364.3M 25.6M Dec/2025
Xeris Pharmaceuticals USD 11.08M 10.46M Dec/2025